What isMelanotan IIFDA Status, Evidence and Risks (2026)
Be first to know.Email the day Melanotan II's FDA or HHS status changes.
Updates only. Doesn't reserve treatment. Unsubscribe anytime. Privacy
Review pending. Off Category 2 since Apr 2026. Not approved by FDA for any use. Not on the 503A bulks list 1,2.
Part of The Sommar Peptide Guide. Melanotan II is sold online as tanning injections and nasal sprays. Education only.
What melanotan II is
Melanotan II is a synthetic analog of alpha-MSH, a hormone that tells skin cells to make melanin, the pigment that darkens skin 3. It acts on several melanocortin receptors, not just the ones in skin, which is why its effects reach beyond tanning 4.
It is sold mainly for tanning, as an injection under the skin or as a nasal spray 5,6.
FDA has approved two related melanocortin drugs for narrow uses. Afamelanotide, an implant, increases pain-free light exposure in people with erythropoietic protoporphyria, a rare light-sensitivity disorder. Bremelanotide, an injection, treats low sexual desire (hypoactive sexual desire disorder) in premenopausal women 7. Melanotan II is neither drug, and those approvals do not carry over to it.
Where FDA stands
- Category 2, until Apr 2026. Melanotan II came off FDA's significant-safety-risk list in Apr 2026, one of 12 peptides removed after their nominations were withdrawn 1,8. FDA still lists it in the withdrawn table, with its safety concerns attached 1.
- Removal approved nothing. Melanotan II is not approved by FDA for any use and is not on the 503A bulks list 2. More in Are Peptides Legal?
- Review pending. FDA's Pharmacy Compounding Advisory Committee is expected to review it before the end of Feb 2027. No date is set 9. Any vote would be advice only.
- Not in the HHS policy. On Oct 28, 2026, HHS filed an interim enforcement discretion policy covering six peptides: BPC-157, TB-500, MOTS-c, epitalon, semax and KPV 14. Melanotan II is not one of them and keeps its prior status, as of Oct 29, 2026.
Regulator warnings
| Year | Regulator | What happened |
|---|---|---|
| 2007 | FDA (US) | FDA sent a warning letter to a company selling melanotan II as an injectable tanning product. FDA said "consumers who are currently using Melanotan II should stop using the product" 10. |
| 2009 | MHRA (UK) | The UK medicines regulator said melanotan "has not been tested for safety, quality or effectiveness" and warned people not to use it 11. |
| 2015 | US Department of Justice | Three people tied to that company pleaded guilty to federal charges. Per DOJ, FDA had warned the company in Aug 2007 and it kept selling melanotan II until Apr 2009 12. |
| 2026 | TGA (Australia) | The TGA warned consumers against melanotan II tanning products, which are not approved as tanning agents there. Its tests of five nasal spray bottles labeled 30 mg found between 22 and 54 mg per bottle 6. |
What the evidence shows
We found no approved use for melanotan II anywhere. What's documented in people is mostly case reports of harm 3,4.
Case reports describe what happened to one person, or a few. They cannot show how often a side effect happens, and they rarely prove the drug caused it.
A 2017 review in the International Journal of Dermatology found case reports linking melanotan use to skin problems, especially changes in existing moles and new atypical (dysplastic) moles 3. It also found four case reports of melanoma arising in existing moles during or shortly after melanotan use. The authors wrote that "conclusive evidence linking these phenomena is lacking" 3.
Known risks and FDA's concerns
FDA's stated concerns first 1:
- Immune reactions. Compounded melanotan II "may pose risk for immunogenicity" for some routes, from aggregation or peptide-related impurities.
- Serious adverse events. Published case reports describe melanoma, posterior reversible encephalopathy syndrome (PRES, a rare brain syndrome tied to swelling), sympathomimetic toxidrome (an adrenaline-like overload) and priapism.
Other effects in the medical literature:
| Effect | What's reported |
|---|---|
| Common effects | Acne, facial flushing, stomach upset and sun sensitivity, per a 2024 dermatology review 5 |
| Nausea, headache, dizziness | Listed in a 2020 case report and literature review 4 |
| Mole changes | Changes in existing moles and new atypical moles 3 |
| Priapism | A painful erection that won't go away. One 2019 case still had no erectile function four weeks after treatment 13 |
| Kidney | A 2020 case of a 45-year-old man with a kidney infarction (blocked blood flow to part of the kidney) after six months of injections. The authors called melanotan II the likely cause but could not prove it 4 |
Dosing adds its own risk. The TGA's tests found up to 54 mg in bottles labeled 30 mg, which it said "further increases the chance of adverse events" 6.
Why it's sold online anyway
Melanotan II is easy to find online, often labeled "research use only." That label is the seller saying the product is not made for people. A 2024 dermatology paper warns there is no guarantee that product bought online is pure 5. It also notes tanning sprays have spread on TikTok. In one 2020 analysis, 12 of 441 pro-tanning videos were about melanotan II 5.
Those products skip a prescriber and any quality check for human use. Prescription vs Research Peptides has more.
Other peptides on this shelf: GHK-Cu, the skin care peptide with a split status, and KPV, a three-amino-acid piece of the same hormone, alpha-MSH.
Asked a lot.
The sources.
- FDA. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (content current as of Apr 22, 2026). Read it
- FDA. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act (content current as of May 14, 2026). Read it
- Habbema L, Halk AB, Neumann M, Bergman W. Risks of unregulated use of alpha-melanocyte-stimulating hormone analogues: a review. Int J Dermatol. 2017. doi:10.1111/ijd.13585. Read it
- Peters B, Hadimeri H, Wahlberg R, Afghahi H. Melanotan II: a possible cause of renal infarction: review of the literature and case report. CEN Case Rep. 2020;9(2):159-161. doi:10.1007/s13730-020-00447-z. Read it
- Newton J, Reinschmidt A, Van Gorp R, Sonstegard A. Nasal tanning sprays: illuminating the risks of a popular TikTok trend. Cutis. 2024;113(1):E3-E4. doi:10.12788/cutis.0933. Read it
- Therapeutic Goods Administration (Australia). Warning about Melanotan II tanning products (infringement notices paid May 2026). Read it
- FDA. Advancing Health Through Innovation: New Drug Therapy Approvals 2019. Read it
- Frier Levitt. FDA Peptides "Do Not Compound" List Update (Apr 16, 2026). Read it
- Holland & Knight. Peptides at a Crossroads: What Wellness Providers Need to Know (Oct 16, 2026). Read it
- Drug Topics. FDA issues warning letter to Melanocorp (Sept 7, 2007). Read it
- Cancer Research UK. Melanotan injections are illegal and possibly unsafe (Jan 28, 2009). Read it
- US Attorney's Office, Middle District of Tennessee. Former owner and employees of Brentwood-based Melanocorp, Inc. plead guilty to federal charges (Mar 11, 2015). Read it
- Dreyer BA, Amer T, Fraser M. Melanotan-induced priapism: a hard-earned tan. BMJ Case Rep. 2019;12(2):e227644. Read it
- HHS. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. Docket HHS-OASH-2026-0496, FR Doc 2026-22192 (filed for public inspection Oct 28, 2026; scheduled to publish in the Federal Register Oct 30, 2026). Read it
Be first to know.
Get an email the day Melanotan II's FDA or HHS status changes. Updates are for education only. Joining doesn't reserve treatment.
Email only. Please don't share health details here. Privacy Policy